CIK 0001783328
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
TScan Therapeutics, Inc.
Sign in to watch- Ticker
- TCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825282075
- Phone
- +1 857-399-9500
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | MacBeath Gavin Chief Executive Officer | Grant or award | +1,000,000 | 1,049,767 | ||
| 2026-10-01 | ZDRAVESKI ZORAN See Remarks | Grant or award | +300,000 | 304,716 | ||
| 2026-05-20 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2026-05-20 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2026-05-20 | Woods Keith Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2026-05-20 | Nicholson Garry A Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2026-05-20 | Gruia Gabriela Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2026-05-20 | Dorton Katina Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2026-05-20 | Klencke Barbara Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2026-01-20 | Amello Jason Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 | ||
| 2026-01-20 | MacBeath Gavin Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,165,000 | 1,165,000 | ||
| 2026-01-20 | Dworak Leiden See Remarks | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-01-20 | Louis Chrystal Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +420,000 | 420,000 | ||
| 2026-01-20 | ZDRAVESKI ZORAN See Remarks | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 | ||
| 2025-12-23 | Lynx1 Capital Management LP 10% owner | Purchase | +6,232 | $0.90 | $6K | 8,019,148 |
| 2025-12-22 | Lynx1 Capital Management LP 10% owner | Purchase | +75,500 | $0.90 | $68K | 8,012,916 |
| 2025-12-19 | Lynx1 Capital Management LP 10% owner | Purchase | +80,069 | $0.90 | $72K | 7,937,416 |
| 2025-06-30 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2025-06-30 | BAKER BROS. ADVISORS LP Director | Grant or award · Non- Qualified Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2025-06-30 | Klencke Barbara Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 |
Page 1 of 8 · 144 trades